trc102

Neoplasm

National Cancer Institute (NCI)Phase 1/2Active

B

59/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 49/ 100
Competitive Position: 89/ 100

Competitive context

927 Active assets in the Neoplasm cohort.

Asset / Sponsor	Phase	Rating
PANITUMUMAB Astellas Pharma Inc	Phase 2	BBB
GRANULOCYTE COLONY-STIMULATING FACTOR LENOGRASTIM Sanofi	Phase 4	BB
LIDOCAINE Medical College of Wisconsin	Phase 4	BB
Glycopyrrolate Medical College of Wisconsin	Phase 4	BB
Vinorelbine Shi Yanxia	Phase 3	BB

View all 50 →

Same molecule, other indications

trc102 is also rated in:

lung large cell carcinomaDormant

B

Indicative ·

60 / 100

lung adenocarcinomaDormant

B

Indicative ·

58 / 100

lung cancerDormant

CCC

Indicative ·

53 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.